ASPEN AEROGELS INC (ASPN)

US04523Y1055 - Common Stock

16.12  +0.02 (+0.12%)

Fundamental Rating

3

ASPN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 84 industry peers in the Chemicals industry. While ASPN seems to be doing ok healthwise, there are quite some concerns on its profitability. ASPN is valued quite expensively, but it does show have an excellent growth rating.



1

1. Profitability

1.1 Basic Checks

ASPN had negative earnings in the past year.
In the past year ASPN has reported a negative cash flow from operations.
In the past 5 years ASPN always reported negative net income.
ASPN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of ASPN (-6.52%) is worse than 83.33% of its industry peers.
ASPN's Return On Equity of -9.39% is on the low side compared to the rest of the industry. ASPN is outperformed by 77.38% of its industry peers.
Industry RankSector Rank
ROA -6.52%
ROE -9.39%
ROIC N/A
ROA(3y)-13.21%
ROA(5y)-15.23%
ROE(3y)-18.92%
ROE(5y)-22.72%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of ASPN (23.85%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of ASPN has grown nicely.
ASPN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.88%
GM growth 5Y14.41%

5

2. Health

2.1 Basic Checks

ASPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ASPN has more shares outstanding than it did 1 year ago.
ASPN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ASPN is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 2.54 indicates that ASPN is not a great score, but indicates only limited risk for bankruptcy at the moment.
ASPN's Altman-Z score of 2.54 is fine compared to the rest of the industry. ASPN outperforms 66.67% of its industry peers.
ASPN has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
ASPN has a Debt to Equity ratio of 0.24. This is in the better half of the industry: ASPN outperforms 76.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z 2.54
ROIC/WACCN/A
WACC8.55%

2.3 Liquidity

A Current Ratio of 3.41 indicates that ASPN has no problem at all paying its short term obligations.
ASPN has a better Current ratio (3.41) than 83.33% of its industry peers.
ASPN has a Quick Ratio of 2.91. This indicates that ASPN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ASPN (2.91) is better than 85.71% of its industry peers.
Industry RankSector Rank
Current Ratio 3.41
Quick Ratio 2.91

7

3. Growth

3.1 Past

ASPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.27%, which is quite impressive.
Looking at the last year, ASPN shows a very strong growth in Revenue. The Revenue has grown by 32.36%.
Measured over the past years, ASPN shows a quite strong growth in Revenue. The Revenue has been growing by 17.99% on average per year.
EPS 1Y (TTM)70.27%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q95%
Revenue 1Y (TTM)32.36%
Revenue growth 3Y33.51%
Revenue growth 5Y17.99%
Revenue growth Q2Q41.28%

3.2 Future

Based on estimates for the next years, ASPN will show a very strong growth in Earnings Per Share. The EPS will grow by 50.06% on average per year.
ASPN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.45% yearly.
EPS Next Y65.61%
EPS Next 2Y73.95%
EPS Next 3Y59.17%
EPS Next 5Y50.06%
Revenue Next Year53.82%
Revenue Next 2Y56.15%
Revenue Next 3Y53.12%
Revenue Next 5Y45.45%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASPN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASPN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ASPN's earnings are expected to grow with 59.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.95%
EPS Next 3Y59.17%

0

5. Dividend

5.1 Amount

No dividends for ASPN!.
Industry RankSector Rank
Dividend Yield N/A

ASPEN AEROGELS INC

NYSE:ASPN (4/29/2024, 9:07:38 AM)

16.12

+0.02 (+0.12%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.24B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.52%
ROE -9.39%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 23.85%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.41
Quick Ratio 2.91
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)70.27%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y65.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)32.36%
Revenue growth 3Y33.51%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y